Lea, R.; Houghton, L.A.; Whorwell, P.J.; Whitaker, P.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA84
Academic Journal
Recent studies suggest that patients with irritable bowel syndrome lBS have elevated levels of plasma 5-HT following meal ingestion compared with healthy controls. Moreover, patients who exhibit postprandial symptoms have higher plasma 5-HT levels compared with those who do not, suggesting a possible relationship between Dost-prandial symptoms and abnormalities in 5-HT release. Given functional dyspepsia (FD) belongs to the same family of disorders as lBS, the aims of this study were to assess platelet depleted plasma (PDP) 5-HT concentrations under fasting and fed (760 kcal meal) conditions in 11 patients with FD (aged 30-61 years; 6 males) and 12 healthy volunteers (aged 20-48 years; 5 males) and assess any relationship to gender and epigastric pain/discomfort (p/d). Results: Under fasting conditions FD patients had similar levels of PDP 5-HT to controls (FD (n = 11): 4.65 ng/ml (geometric mean) vs controls (n = 12): 4.57ng/ml; ratio FD:controls (95%CI), 1.02 (0.14, 1.26)). However, under fed conditions, although the peak PDP 5-HT concentration for the whole group of FD patients was not significantly different from controls (11.19 ng/ml vs 8.43 ng/ml; 1.33(0.69, 2.54); p = 0.37, patients who reported post-prandial p/d had a higher PDP 5-HT peak (n = 8:14.74 ng/ml) than both patients who did not report p/d (5.36ng/ml; ratio with:without p/d 2.75(1.24, 6.10); p = 0.02) and controls (8.43 ng/ml; ratio FD with p/d:controls, 1.75 (0.79, 3.87); p = 0.14). This was as a consequence of a higher PDP 5-HT peak in the female FD patients with p/d (36.56 ng/ml), as all other females (FD and controls (n = 9): 7.71 ng/ml; ratio FD with p/d:FD and controls 4.74 (2.5, 9.0 p < 0.001) and all males (FD and contro s (n = 11): 8.07 ng/ml; ratio female FD with p/d: all males, 4.53 (2.19,9.35); p < 0.001) had lower PDP 5-HT peaks. Lastly, symptom severity tended to correlate with peak PDP 5-HT concentration (rho = 0.37; p = 0.08). Conclusions: These data provide evidence for a role...


Related Articles

  • Of actors, bolting horses, and rops in oceans! Cremonini, F.; Camilleri, M. // Gut;May2003, Vol. 52 Issue 5, p619 

    Examines whether serotonin mediates postprandial symptoms in irritable bowel syndrome (IBS). Components of the colonic contractile response to meals of IBS patients; Reasons behind the differences in circulating serotonin levels in IBS.

  • Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Houghton, L.A.; Atkinson, W.; Whitaker, R.P.; Whorwell, P.J.; Rimmer, M.J. // Gut;May2003, Vol. 52 Issue 5, p663 

    Background: Meal ingestion is often associated with exacerbation of gastrointestinal symptoms in subjects with irritable bowel syndrome (lBS). Furthermore, recent preliminary data suggest that 5-hydroxytryptamine (5-HT) concentration in platelet poor plasma is elevated following meal ingestion...

  • Serotonin's Role in IBS.  // BioWorld Today;5/10/2010, Vol. 21 Issue 89, Special section p2 

    The article reports on the serotonin gene variants identified by a research team at Mayo Clinic which impact irritable bowel syndrome (IBS).

  • Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Miller, David P.; Alfredson, Tanya; Cook, Suzanne F.; Sands, Bruce E.; Walker, Alexander M. // American Journal of Gastroenterology;May2003, Vol. 98 Issue 5, p1117 

    : ObjectiveAlosetron hydrochloride (Lotronex), a potent selective 5-hydroxytryptamine3 receptor antagonist, was approved in February, 2000 in the United States for the treatment of diarrhea-predominant irritable bowel syndrome (IBS) in women. Marketing was suspended in November, 2000, after...

  • Tegaserod: A Viewpoint by Peter J. Whorwell. Whorwell, P.J. // Drugs;Sep1999, Vol. 58 Issue 3, p497 

    Comments on a study on the use of serotonin drug in the treatment of irritable bowel syndrome (IBS). Background of IBS; Use of tegaserod in the treatment of IBS; Problems regarding the development of drugs for the treatment of IBS.

  • Tegaserod: A Viewpoint by M. Scott Harris. Harris, M.S. // Drugs;Sep1999, Vol. 58 Issue 3, p497 

    Discusses a study on the use of tegaserod serotonin drug in the treatment of irritable bowel syndrome. Symptoms and manifestation of the disease; Diagnosis and treatment; Mechanism of action of tegaserod.

  • Tegaserod. Scott, L.J.; Perry, C.M. // Drugs;Sep1999, Vol. 58 Issue 3, p491 

    â–´ Tegaserod is a serotonin (5-hydroxytryptamine; 5-HT) receptor partial agonist which has been investigated for the treatment of irritable bowel syndrome (IBS). Specifically, it binds with high affinity to human 5-HT receptors, thereby stimulating the release of neurotransmitters and the...

  • Diet Spells R-E-L-l-E-F from IBS. Palmer, Sharon // Environmental Nutrition;Oct2011, Vol. 34 Issue 10, p1 

    The article offers information on the symptoms, diagnosis and treatment of irritable bowel syndrome (IBS). It says that abdominal pain, constipation and diarrhea are some of the common symptoms experienced by IBS patients. The diagnosis of the disease is based on recurrent abdominal pain and...

  • Ranking of symptoms by patients with the irritable bowel syndrome. Maxton, D.G.; Morris, J.A.; Whorwell, P.J. // BMJ: British Medical Journal (International Edition);11/4/89, Vol. 299 Issue 6708, p1138 

    Examines the symptoms of irritable bowel syndrome among patients in Great Britain. Main symptoms of the bowel syndrome; Prevalence of non-colonic symptoms; Advice on the management of the symptoms.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics